FDA approved the original new drug application for ZANVASTRO on September 3, 2026, sponsored by IONIS PHARMS INC. FDA classed the original submission Type 1 - New Molecular Entity. FDA’s record shows no approved efficacy supplement on the application since.
- Application
- NDA220210
- Sponsor
- IONIS PHARMS INC
- Original approval
- Review
- priority review
- Submission class
- Type 1 - New Molecular Entity
- Active ingredient
- zilganersen
Browse every approval whose brand starts with Z, every approval FDA granted in 2026, or the complete response letters FDA has published — the applications it did not approve.
Or read a company the way this approval lands on it: open Moderna in the terminal. Pipeline, cash and a valuation whose assumptions you can change — Moderna is open as a sample, no account needed.
Products under this application
| Ingredient and strength | Form | Route | Marketing status |
|---|---|---|---|
| zilganersen 50MG | INJECTION | SOLUTION | Prescription |
Approved efficacy supplements
An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.
FDA’s record shows no approved efficacy supplement on this application.
Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-15). Every field on this page comes from that record.
Other approvals to IONIS PHARMS INC
An approval date is the start of the question, not the end
What a drug is worth to the company that owns it depends on what else is in the pipeline, how much cash is behind it and who else is running the same trial. The FuzeBio terminal puts those on one page for a company, with a valuation whose assumptions you can change. Moderna is open as a sample, no account needed.
Open Moderna in the terminalEvery panel works on a sample. No sign-up.